Lesinurad (Zurampic®)
Lesinurad (Zurampic®) for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.
| NCPE Assessment Process | Ongoing |
| Rapid review received | 15/03/2017 |
| Rapid review completed | 20/03/2017 |
| Rapid Review outcome | Full pharmacoeconomic assessment recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 29/03/2017 |
| Pre-submission consultation with Applicant | 22/05/2017 |
| Submission received from Applicant | 07/06/2018 |
| Preliminary review sent to Applicant | 18/07/2018 |
| NCPE assessment re-commenced | 15/08/2018 |
| Factual accuracy sent to Applicant | 15/11/2018 |
| NCPE assessment re-commenced | 21/11/2018 |
| NCPE Assessment Complete | 06/12/2018 |
| NCPE assessment outcome | The NCPE recommends that lesinurad not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |